ral Register Notice: FDA will hold a public meeting 12/16 to discuss the proposed recommendations for a user fee program for biosimilar biological products for fiscal years 2013 through 2017. The meeting will be held from 9 a.m. to 1 p.m. at FDA’s White Oak Campus, 10903 New Hampshire Ave., Bldg. 31, Rm. 1503, Silver Spring, MD. Contact Rokhsana Safaai-Jazi, 796–4463. To view this notice, click here.
